Pfizer cans PF-08046045, but keeps PF-08046044 for now.
ApexOnco Front Page
Recent articles
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
The same trial that sent Summit up 272% sees the stock crash 36%.
But sasanlimab's use looks set to remain narrow.
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
Can activity at CTLA-4 be added to PD-1 x VEGF blockade?
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
